Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Individual Dopaminergic Neurons Show Raised Iron Levels in Parkinson Disease
Neurol 68:1820-1825, Oakley,A.E.,et al, 2007
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Occurrence of Different Cancers in Patients with Parkinson's Disease
BMJ 310:1500-1501, Moller,H.,et al, 1995
Disabling Parkinsonism Due to Lithium: A Case Report
J Geriatr Psychiatry Neurol 8:118-119, Holroyd,S. & Smith,D., 1995
Magnetic Resonance Imaging of Brain Iron in Health and Disease
J Neurol Sci 134:19-26,1, Vymazal,J.,et al, 1995
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Drug-Induced Movement Disorders:An Overview
In Movement Dis in Neurol & Neuropsych, Blackwell Sci Publ, Boston, 2:21., Miller,L.G.&Jankovic,J., 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Parkinsonism and Amiodarone Therapy
Ann Neurol 25:630-632, Werner,E.G.&Olanow,C.W., 1989
Mild Parkinsonism in Persons Exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
Neurol 39:1483-1487, Tetrud,J.W.,et al, 1989
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Parkinsonism, Tremor, and Depression Induced by Cinnarizine and Flunarizine
BMJ 297:722-723, Capella,D.,et al, 1988
Bromocriptine Induced Impotence in Parkinson's Disease
BMJ 295:367-368, Cleves,L., 1987
Parkinsonism, Tardive Dyskinesia, Akathisia, & Depression Induced by Flunarizine
Lancet 1:1303-1304, Chouza,C.,et al, 1986
Drug-Induced Parkinsonism in the Elderly
Lancet 2:1082-1083, Stephen,P.J.,et al, 1984
Parkinson's Disease in a Chemist Working with l-Methyl-4-Phenyl-1, 2, 5, 6-Tetrahydropyridine
NEJM 309:310, Langston,J.W.,et al, 1983
Taste & Smell in Disease (First of Two Parts)
NEJM 308:1275-1279, Schiffman,S.S., 1983
A Danger In Making The Diagnosis Of Parkinson's Disease
Lancet 1:1212-1213, Murdoch,P.S.,et al, 1982
Reversible Drug-Induced Parkinsonism
Arch Neurol 39:644-646, Rajput,A.H.,et al, 1982
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Respiratory Dyskinesias:Extrapyramidal Dysfunction & Dyspnea
Ann Int Med 88:327, Weiner,W.J.,et al, 1978
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Beware of Deep Water After Subthalamic Deep Brain Stimulation
Neurol 94:39-41, Waldvogel, D.,et al, 2020
Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020